The Impact Of Cystic Fibrosis On The Immunologic Profile Of Pediatric Patients. by Bernardi, Daniela M et al.
0021-7557 © 2013 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. 
http://dx.doi.org/10.1016/j.jped.2013.02.007
J Pediatr (Rio J). 2013;89(1):40−47
www.jped.com.br
☆Please, cite this article as: Bernardi DM, Ribeiro AF, Mazzola TN, Vilela MM, Sgarbieri VC. The impact of cystic fibrosis  
on the immunologic profile of pediatric patients. J Pediatr (Rio J). 2013;89:40-47.
* Corresponding author.
E-mail: dani_miotto@yahoo.com.br (D.M. Bernardi).
ORIGINAL ARTICLE
The impact of cystic fibrosis on the immunologic profile  
of pediatric patients☆
Daniela M. Bernardia,*, Antonio F. Ribeirob, Tais N. Mazzolac, Maria M.S. Vilelad,  
and Valdemiro C. Sgarbierie
a MSc in Food and Nutrition. Department of Food and Nutrition, School of Food Engineering, Universidade Estadual de 
Campinas (UNICAMP), Campinas, São Paulo, Brazil
b PhD in Child and Adolescent Health. Center for Investigation in Pediatrics, Department of Pediatrics, Medical School, 
UNICAMP, Campinas, São Paulo, Brazil 
c MSc in Child and Adolescent Health. Center for Investigation in Pediatrics, Department of Pediatrics, Medical School, 
UNICAMP, Campinas, São Paulo, Brazil
d PhD in Biology (Immunology). Center for Investigation in Pediatrics, Department of Pediatrics, Medical School, 
UNICAMP, Campinas, São Paulo, Brazil
e PhD in Nutrition. Department of Food and Nutrition, School of Food Engineering, UNICAMP, Campinas, São Paulo, Brazil
Received 18 June 2012; accepted 22 August 2012
KEYWORDS
Cystic fibrosis;
Reactive oxygen 
species;
Glutathione;
Cytokines;
Immunoglobulins
Abstract 
Objective: To compare the immunologic state of 44 pediatric patients with cystic fibrosis 
(CF) with a control group consisting of 16 healthy individuals. 
Methods: CF patients aged 3 to 12 years with moderate to good clinical score were 
selected for the study. Erythrocytic glutathione, production of reactive oxygen species, 
cytokines (TNF-a, IFN-g, IL-8, IL-6, IL-10) in peripheral blood mononuclear cells cultures 
under spontaneous and BCG- or PHA-stimulated conditions, serum concentrations of 
TGF-b2, IgA, IgG, IgM, IgE, and salivary IgA were evaluated. 
Results: The spontaneous production of TNF-a, IL-6, and IL-10, the PHA-stimulated 
production of IL-6, and the serum TGF-b2, IgA, and IgG were increased in samples from 
CF patients. Healthy subjects had a higher production of TNF-a in response to BCG. 
Conclusion: Although CF patients appeared clinically stable, the results of their peripheral 
blood examinations demonstrated an impact on the immune system. 
© 2013 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. 
07 Org 40-47.indd   40 4/3/13   12:46:23
Este é um artigo Open Access sob a licença de CC BY-NC-ND
Este é um artigo Open Access sob a licença de CC BY-NC-ND
Immunologic profile of cystic fibrosis patients 41
PALAVRAS-CHAVE
Fibrose cística;
Espécies reativas de 
oxigênio;
Glutationa; 
Citocinas;
Imunoglobulinas
Introduction
Cystic fibrosis (CF) is the most common severe Mendelian 
disease in infancy; it has a recessive autossomic character, 
and is more common in whites. The CF gene codifies a 
protein with 1,480 amino acid residues, identified as cystic 
fibrosis transmembrane conductance regulator (CFTR). 
This protein is present mainly in the epithelial cells of 
the airways, gastrointestinal tract, sweat glandules, and 
genitourinary system. CFTR functions as a chloride channel 
in the apical membrane of epithelial cells, and also has 
other important regulatory functions. Gene mutations may 
lead to the absence or malfunctioning of CFTR, contributing 
to the development of CF.1,2
There is agreement that neutrophils and the existence of 
mutation in the CFTR gene play a role in CF inflammation. 
The increase in the reabsortion of sodium into the 
epithelial cells causes an elevated production of adenosine 
triphosphate (ATP) and, consequently, an increase of 
intracellular hydrogen peroxide and mitochondrial 
reactive oxygen species (ROS). Thus, it is possible that 
the production of ROS is responsible for the initiation 
and maintenance of the inflammatory process, when the 
excessive production of ROS activates the nuclear factor 
kappa-B (NF-kB) pathway and increases the transcription 
of pro-inflammatory cytokines that may increase the 
production of ROS, perpetuating the cycle.3,4
The defect in ROS neutralization may also be responsible 
for the oxidative stress in CF. CFTR is also involved in the 
transportation of glutathione (GSH) into the epithelial 
cells; thus, it is possible that the transportation of GSH 
is faulty in epithelial cells in patients with CF. GSH also 
prevents the degradation of NF-kB-inhibitor (I-kB) and 
therefore, low levels of intracellular GSH may promote the 
activation of NF-kB, further increasing the concentration of 
pro-inflammatory cytokines, and consequently reducing the 
production of the anti-inflammatory cytokines.3,4
A large number of studies has shown that inflammation 
has both local and systemic effects, and the improved 
clinical status of the patients mainly results from a better 
understanding of the natural course of disease, in particular 
inflammation. In this context, the aim of this study was to 
evaluate the inflammatory response and the immunological 
profile of patients with CF aged 3 to 12 years with a clinical 
score between moderate and good.
Methods
This cross-sectional study was conducted between January, 
2009 and March, 2010. The inclusion criteria for CF patients 
were: diagnosis of CF confirmed by two tests showing elevated 
sodium and chloride concentrations and/or identification of 
two mutated alleles in the CFTR gene, patients between 
3 and 12 years old, vaccinated with the BCG vaccine, and 
Shwachman score between moderate and good. 
Regarding the healthy control group, the inclusion 
criteria were: age between 3 and 12 years, absence of 
clinical manifestations of disease, no family history of 
chronic disease, and vaccinated with the BCG vaccine. 
Exclusion criteria for the control group were: use of anti-
inflammatory drugs, and report of fever or any injury a 
week before blood collection.
Parents or legal guardians of the children were informed 
about the objectives and methods employed in research, 
and being aware of the procedures and discomforts to which 
children would be submitted, with a capacity of free will 
and without coercion, were requested to sign the informed 
consent. The study protocol was approved by the Research 
Ethical Committee of the Medical School of Universidade 
Estadual de Campinas (UNICAMP), under No. 538/2008.
The survey was conducted with patients from the CF 
pediatrics outpatient unit, UNICAMP’s Clinic Hospital, 
Campinas, São Paulo, Brazil. Fifty-two patients met the 
O impacto da fibrose cística no perfil imunológico de pacientes pediátricos
Resumo 
Objetivo: Comparar o estado imunológico de 44 pacientes pediátricos com fibrose cística 
(FC) a um grupo-controle formado por 16 indivíduos saudáveis. 
Métodos: Foram selecionados para o estudo pacientes com FC com idade entre 3 e 12 
anos, apresentando um escore clínico moderado e bom. Foram avaliados a glutationa 
eritrocitária, a produção de espécies reativas de oxigênio, citocinas (TNF-a, IFN-g, IL-8, 
IL-6, IL-10) em culturas de células mononucleares do sangue periférico em condições 
espontâneas e estimuladas por BCG ou PHA, a concentração sérica de TGF-b2, IgA, IgG, 
IgM, IgE e IgA salivar. 
Resultados: A produção espontânea de TNF-a, IL-6 e IL-10, a produção de IL-6 estimula-
da por PHA e TGF-b2, IgA e IgG séricas aumentaram em amostras de pacientes com FC. 
Indivíduos saudáveis tiveram uma produção mais elevada de TNF-a em resposta a BCG. 
Conclusão: Apesar de os pacientes com FC parecerem clinicamente estáveis, os resul-
tados de seus exames de sangue periférico mostraram que houve um impacto sobre o 
sistema imunológico.
© 2013 Sociedade Brasileira de Pediatria. Publicado por Elsevier Editora Ltda. 
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inclusion criteria, and 44 agreed to participate. The group of 
healthy children was also recruited in Campinas, São Paulo. 
Twenty-one children were invited to enroll in the research, 
but only 16 met the established inclusion criteria.
Blood and saliva collection 
Sample collections were performed by the department of 
clinical pathology of UNICAMP’s Clinic Hospital. Eighteen 
milliliters (18 mL) of peripheral venous blood were collected 
only once, through standardized techniques in appropriate 
tubes for each procedure, after at least four hours of 
fasting. One milliliter (1 mL) of saliva was collected with 
plastic, sterile Pasteur pipette. The patients were advised 
to perform oral hygiene by washing with pure water. After 
collection, aliquots of saliva were centrifuged at 1 g for 7 
min and stored at -80°C until analysis. 
Complete blood count
The overall and differential count of blood cells was 
accomplished through the Cobas-Argos 5 Diff (Roche 
Diagnostic), in the department of clinical pathology of 
UNICAMP’s Clinic Hospital. 
Erythrocyte reduced glutathione
The assay was performed using a minor modification in 
the method described by Beutler.5 Two hundred microliters 
(200 µL) of peripheral blood EDTA were lysed with 1.8 mL 
of distilled water. Then, 2 mL of 1.67% metaphosphoric 
acid solution were added, and the mixture was filtered. 
Four milliliters (4 mL) of 0.3M Na2HPO4 solution were 
added to 1 mL of the clear filtrate and read at 412 nm on 
a Beckman spectrophotometer. A second optical density 
reading was taken after the addition of 100 mL of dithiobis-
nitrobenzoic acid (DTNB) solution to the filtrates. Results 
were expressed as mg/dL.
Production of reactive oxygen species by 
granulocytes
Measurements were performed by the modified 
technique of Emmendörffer et al.6 and Richardson et al.7 
Dihydrorhodamine 123 (DHR 123) was used to quantify 
phorbol-12-myristate-13-acetate (PMA)-stimulated ROS 
production by granulocytes from peripheral blood. After 
lysing the erythrocytes, the events were recorded in 
an Epics XL-MCL flow cytometer (Beckman-Coulter – 
USA). Forward and side scatters were used to gate 
granulocytes. Basal ROS production was determined 
as the percentage of fluorescent events without PMA 
stimulus. PMA-stimulated ROS production was measured 
through the ratio of median fluorescence from PMA-
stimulated granulocytes and median fluorescence from 
non-stimulated granulocytes.
Cytokine concentration in culture supernatant
The analysis of cytokine production was performed by the 
culture of peripheral blood mononuclear cells (PBMC), 
modified from the protocol of Gaines et al.8 Lyophilized 
BCG (Moreau Rio de Janeiro vaccine vials) were freshly 
reconstituted with the culture medium RPMI 1640 (Sigma – 
USA) and used at 5×105 UFC/mL. Phytohemagglutinin (PHA, 
Sigma – USA) was used as a positive control at 7.5 µg/mL. 
PBMC was diluted to 2×106 cells/mL in supplemented RPMI, 
and incubated for 48 h (37 ºC) in round-bottomed 96-well 
tissue culture plates with BCG, or PHA, or medium alone. 
The cultures’ supernatants were collected and stored at 
−80 ºC for enzyme linked immunosorbent assay (ELISA). 
Commercial kits (DuoSet, RD Systems – USA) were used to 
measure interferon-g (IFN-g), tumor necrosis factor-a (TNF-
a), and interleukins (IL-10, IL-8 and IL-6) concentrations, as 
recommended by the manufacturer. All samples and points 
of the standardized curves were measured in duplicate. 
The results were expressed in ρg/mL. 
Concentration of transforming growth factor-b2 in 
blood serum
The transforming growth factor-b2 (TGF-b2) dosage was 
performed by ELISA (DuoSet, RD Systems – USA). The assays 
were performed following the manufacturer’s protocols. 
The results were expressed in ρg/mL. 
Serum immunoglobulins (IgA, IgG, IgM e IgE) and 
salivary IgA 
The determination of serum concentration of 
immunoglobulins (IgA, IgG, IgM, IgE) and salivary IgA were 
performed by nephelometry. 
Statistical analyses
All the results were analyzed using the Statistical Package 
for Social Sciences (SPSS) for Windows, version 7.5.1 - 
USA. Data analysis was performed with Student’s t-test, 
Mann-Whitney’s test, and Spearman’s test. Significance 
was defined as p-value < 0.05. GraphPad Prism (version 
4.0, GraphPad Software – USA) was used to plot GSH, ROS 
production, cytokines, and immunoglobulins graphical data.
Results
In the present study 44 children with CF and 16 healthy 
subjects were included, paired by age. Table 1 shows the 
characteristics of the CF patients and healthy subjects. 
As illustrated in Table 1, patients with CF and healthy 
subjects were paired by age. Regarding the colonization 
of the airways of patients, there was a high prevalence of 
colonization by Staphylococcus aureus, a relatively high 
presence of Pseudomonas aeruginosa and Pseudomonas 
aeruginosa mucoid, and a low incidence of Burkholderia 
cepacea.
The median values of leukocyte and erythrocyte cell 
numbers for the CF patients and healthy control group are 
shown in Table 2.
The number of total leukocytes was higher for the group of 
patients with CF. Mean corpuscular hemoglobin (MCH) and mean 
corpuscular volume (MCV) were both lower for CF children.
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Glutathione in the erythrocytes, basal, and PMA-stimulated 
ROS production are shown in Figure 1. Erythrocytic GSH, 
basal, and PMA-stimulated production of ROS did not differ 
between healthy and CF groups. 
Figure 2 shows the cytokines (TNF-a, IFN-g, IL-8, IL-6, 
and IL-10) concentration in PBMC culture supernatants, 
serum TGF-b2, and immunoglobulins (IgA, IgG, IgM, and IgE) 
from patients with CF compared to healthy children. 
Patients with CF had significantly higher spontaneous 
production of IL-6, TNF-a, IFN-g, and IL-10 than the healthy 
subjects. PHA-stimulated production of IL-6 was also higher 
in CF patients. Healthy children showed higher production 
of TNF-a in BCG-stimulated PBMC when compared to 
CF patients. No difference between the two studied 
groups was observed for the other culture conditions. The 
concentration of TGF- b2 in the blood serum of CF patients 
was higher than in healthy children. 
IgA and IgM concentrations were higher for CF patients, 
compared to healthy subjects. No significant differences 
were observed between groups for IgG and IgE. 
Table 1 Characterization of cystic fibrosis patients’ group and healthy control group.
Study variables CF patients (n = 44) Healthy subjects (n =16)
Characteristics 
Age (months) 101.18±38.4a 99.63±31.6a
Gender (female/male) 22/22 12/4
Shwachman score 75 (40-85)b –
Associated disease
Pancreatic insufficiency  44 –
Hepatic disease 17 –
Diabetes 3 –
Genetic study (CFTR mutation)
ΔF508 homozygote 14 –
ΔF508 heterozygote/R1162X 2 –
 1 –
ΔF508 heterozygote/N1303K 1 –
ΔF508 heterozygote/G542X 23 –
 4
ΔF508 heterozygote/Unknown 34 −
Colonization 16 −
Staphylococcus aureus  11 −
Pseudomonas aeruginosa 
Pseudomonas aeruginosa mucoid 3
Burkholderia cepacia
CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator.
aParametric data: mean ± standard deviation.
bNon parametric data: median (minimum-maximum).
Table 2 White blood cells and red blood cells in patients with cystic fibrosis and in healthy subjects.
Variables Patients with CF Healthy subjects p*
WBC (x103/mm3) 9.91 (5.45-22.38) 6.39 (1.79-8.66) < 0.001
LINFO (x103) 3.89 (2.27-6.67) 2.79 (1.92-4.99) 0.006
MONO (x103) 0.65 (0.11-3.44) 0.42 (0.24-0.91) 0.003
NEU (x103) 4.82 (2.18-11.28) 3.13 (1.44-5.06) 0.001
RBC (x106/mm3) 4.91 (4.18-5.74) 4.82 (4.17-5.24) 0.087
HCT (%) 39.5 (34.1-45.3) 40.55 (34.1-45) 0.366
HGB (g/dL) 13.05 (11.4-15.2) 13.35 (11.1-14.8) 0.503
MCH (pg) 27.1 (20.8-29.9) 28.4 (24,2-30.7) 0.011
MCHC (g/dL) 33.4 (29.7-35.3) 33 (30.5-34.5) 0.375
MCV(fL) 80.75 (69-88.1) 85.1 (79.2-89.7) <0.001
Data expressed as median (minimum – maximum).
CF, cystic fibrosis; HCT, hematocrit; HGB, hemoglobin concentration; LINFO, lymphocytes; MCH, mean corpuscular hemoglobin; 
MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; MONO, monocytes; NEU, neutrophils; RBC, red 
blood cells; WBC, white blood cells. 
*Mann-Whitney’s test.
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Salivary IgA did not differ between the two groups, with 
median 7 mg/dL (from 1.3 to 52.5 mg/dL) for CF patients 
and 7.8 mg/dL (from 1.8 to 14.8 mg/dL) for healthy 
children. 
There was a positive correlation between the Shwachman 
score and production of IL-6 in BCG-stimulated PBMC (p = 
0.04), production of IFN-g in BCG-stimulated PBMC (p = 
0.03), and salivary IGA concentrations (p = 0.02). There 
was a negative correlation between the Shwachman 
score and IgM concentration in serum (p = 0.04), and IgG 
concentration in serum (p = 0.004).
Discussion
Analyzing the ROS production by peripheral granulocytes, it 
was verified that patients with CF did not show differences 
in basal or stimulated production in relation to the healthy 
children group. Differently from these data, ROS levels in two 
human CF lung epithelial cell lines were elevated compared 
with two non-CF controls.9 The increase of oxidation in the 
respiratory epithelium results directly from the absence 
Figure 1 GSH in the erythrocytes, basal, and PMA-stimulated 
production of ROS of patients with CF () and healthy children 
(). (A) Concentration of GSH in the erythrocytes (mg/dL), for 
CF patients () n = 42 and normal () n = 16; (B) percentage 
(%) of basal production of ROS, for CF () n = 44 and normal 
() n = 16 (C); PMA-stimulated ROS production, for CF () 
n = 44 and normal () n = 16. For all analyses, p > 0.05. CF, 
cystic fibrosis; GSH, glutathione; PMA, phorbol-12-miristate-
13-acetate; ROS, reactive oxygen species.
of CFTR function, or indirectly from the infiltration of 
inflammatory cells that produce a high quantity of hydrogen 
peroxide, as well as from a defective antioxidant system 
incapable of controlling the production of ROS.3
In the present study, it was observed that the glutathione 
concentration in peripheral erythrocytes from CF patients 
was not different from the group of healthy subjects. Other 
authors reported similar data, along with an inverse relation 
between erythrocytic GSH and pulmonary function in adult 
CF patients.10 The same correlation was identified between 
lymphocytic GSH and pulmonary function in children with 
CF.11 In apical respiratory epithelium, a reduction of GSH 
was observed, and CFTR was responsible for the abnormal 
transportation of this tripeptide, which may indicate that 
CFTR is involved in maintaining the redox state of the 
airways.12
This oxidative/antioxidative agent imbalance associated 
with impaired metabolism of intracellular Ca+2 and pro-
inflammatory cytokines activate the toll-like receptors 
(TLR) in the epithelial cells. The consequence is the 
activation of NF-kB and AP-1, resulting in the transcription 
of pro-inflammatory cytokines leading to the herding of 
neutrophils and macrophages to the region, increasing the 
production of ROS.3
As shown in this study, BCG-stimulated production of 
TNF-a in PBMC cultures was lower in CF subjects. However, 
the spontaneous cell production of this cytokine was higher 
in these patients. These results may indicate low BCG 
cellular memory in CF patients. Conversely, serum TNF-a 
concentration in adults and adolescents with CF was higher 
than in normal subjects.13
TNF-a concentration in the bronchoalveolar lavage fluid 
and in the sputum of children and adults with CF was 
elevated compared to healthy subjects.14-17 Children with 
CF chronically infected with P. aeruginosa had higher levels 
of TNF-a in their sputum.18
IFN-g is closely involved in the inflammatory process 
and pulmonary function of CF patients. The results shown 
here reveal that there is a difference in the spontaneous 
production of IFN-g among normal subjects and patients 
with CF, and that there was a positive correlation between 
the Shwachman score and the production of INF-g in BCG-
stimulated PBMC. In a study by Moser et al.,19 low quantities 
of IFN-g and high quantities of IL-4 were observed in PBMC 
of patients with CF chronically infected by P. aeruginosa, 
when compared to non-infected adult patients. In bronchial 
biopsy of patients with CF, a higher concentration of IFN-g 
was associated with less aggressive disease, while low 
expression was associated with the presence of acute 
lung disease with frequent exacerbations.20 Therefore, CF 
patients with high concentration of IFN-g and predominant 
response of type TH1 cells have better lung function. 
In the present study, no difference in IL-8 production 
from PBMC cultures between patients with CF and healthy 
subjects could be demonstrated. A high concentration of 
IL-8 was identified in the bronchoalveolar lavage fluid of CF 
patients, even when infection was absent.14 However, other 
studies identified significantly elevated concentrations 
only in patients that showed low pulmonary function.21 The 
concentration of IL-8 in the sputum was also increased, as 
shown in a series of studies.16-18
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Figure 2 Cytokine concentration in the supernatant of PBMC culture (TNF-a, IFN-g, IL-8, IL-6 and IL-10), and serum TGF-b2 and 
immunoglobulin concentration (IgA, IgG, IgM and IgE) from patients with CF () and healthy children (). The cytokine production 
in the supernatant of the PBMC culture was performed in non-stimulated cultures (spontaneous), stimulated by BCG or PHA, for 
48 hours. (A) TNF-a production (pg/mL); (B) IFN-g production (pg/mL); (C) IL-8 production (pg/mL); (D) IL-6 production (pg/mL); 
(E) IL-10 production (pg/mL); (F) concentration of TGF-b2 (pg/mL) in the blood serum; (G) IgA serum concentration (mg/dL); (H) 
IgG serum concentration (mg/dL); (I) IgM serum concentration (mg/dL); (J) IgE serum concentration (IU/dL). The statistical test 
used was Mann-Whitney’s, at *p < 0.05, **p < 0.01, ***p < 0.001. IFN-g, interferon-g; IgA, IgG, IgM, and IgE, immunoglobulins; IL-10, 
IL-8, and IL-6, interleukins; PHA, phytohemagglutinin; TGF-b2, transforming growth factor-b2; TNF-a, tumor necrosis factor-a.
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The present findings revealed a higher spontaneous 
production of IL-6 in PBMC cultures of patients with CF, as 
well as in response to PHA; a positive correlation between 
the Shwachman score and the production of IL-6 in BCG-
stimulated PBMC was also observed. During exacerbation 
and the clinical stability period, serum concentration of 
IL-6 in adult patients with CF was increased, and only 
after treatment with antibiotics did the serum levels of 
IL-6 returned to normal.22 The concentration of IL-6 in the 
bronchoalveolar lavage fluid was increased in CF patients 
infected with P. aeruginosa, similar to normal subjects 
in non-infected patients.15 In the sputum, the levels of 
IL-6 were significantly lower in CF patients in relation to 
healthy subjects.16 IL-6 exerts both inflammatory and anti-
inflammatory effects.23
In the present study, a high production of IL-10 was 
observed under spontaneous and PHA-stimulated conditions 
in PBMC cultures of CF patients. Lower levels of IL-10 were 
also observed in PBMC cultures from subjects with CF, in 
the presence of the tetanus toxoid, compared to healthy 
subjects.24 Bonfield et al., in 1995,15 were the first to show 
that the levels of IL-10 in the bronchoalveolar lavage fluid 
of patients with CF were significantly lower than in healthy 
subjects. 
In this study, blood serum levels of TGF- b2 of CF patients 
were higher than in healthy subjects. In bronchial biopsy 
of patients with CF, higher expressions of TGF-b1 were also 
found for patients with mild pulmonary disease, while in 
patients with frequent exacerbation the concentration was 
relatively lower.20 Regarding the plasma concentration of 
TGF-b1, normal levels were found in patients with normal 
hepatic function, and low levels were observed in patients 
with hepatic disease.25
The higher spontaneous cellular production of IL-10 
and the higher concentration of TGF-b2 in the serum of 
the patients with CF, compared with healthy children, 
could be an adaptive response to the inflammatory status 
that occurs in this disease, since these two cytokines 
are considered important modulators of inflammation. 
Regarding these results, the normal values for ROS 
production by granulocytes and glutathione concentration 
in erythrocytes from CF patients are justified.
The present findings revealed that the levels of salivary 
IgA in patients with CF did not differ from those of 
healthy patients, and a positive correlation between the 
Shwachman score and salivary IGA concentrations was 
observed. Some researchers have reported high levels of 
serum IgA, with normal levels of salivary IgA,26 while others 
have documented higher saliva and serum IgA in patients 
with CF, when compared to healthy subjects.27
Most patients with CF evaluated in the present study 
showed serum levels of IgA, IgG, and IgM within the 
parameters of normality; however, when compared with 
healthy subjects, the concentration in the serum IgA and 
IgM was higher for CF patients, and a negative correlation 
between the Shwachman score and the IgM and IgG 
concentration in serum was observed. Some authors showed 
higher concentrations of serum IgA, IgG, and IgM in patients 
with CF than in normal and asthmatic subjects; additionally, 
the levels of IgG and its subclasses showed correlation to 
the levels of IgA.28 
In a study with 419 CF patients, it was observed that 
patients under 10 years of age had decreased IgG; however, 
older subjects showed normal or higher levels. The authors 
concluded that, with the progression of the pulmonary 
disease, these patients become more susceptible to develop 
hypergammaglobulinemia.29 Similar results were obtained in a 
five-year prospective study, in which hypogammaglobulinemia-G 
was associated to the best weight for the age, fewer 
hospitalizations for pulmonary exacerbations, less colonization 
by P. aeruginosa, and consequently lower decline in pulmonary 
function over the time.30 
Patients with CF suffer from airway colonization and 
infection by a variety of organisms, whose host immune 
responses lead to chronic inflammation and respiratory 
failure. Staphylococcus Aureus, Haemophilus influenza, P. 
aeruginosa,31 and nontuberculous mycobacteria (NTM) are 
among such opportunistic pathogens.32 The CF patients in 
this study showed a high prevalence of colonization by S. 
aureus (77%) and P. aeruginosa (36%), and many of them 
had already been colonized by mucoid. Infection with P. 
aeruginosa affects the longevity of CF patients.33 Initially, 
the infection occurs in different periods and is non-mucoid. 
Over time, P. aeruginosa infection becomes mucoid and 
can lead to biofilm formation, with high resistance to the 
action of antibiotics and innate immune responses.34
The present results demonstrated that patients with 
CF have a variety of small but significant alterations 
compared to healthy children, such as a higher number 
of total leukocytes, higher spontaneous production of 
proinflammatory interleukins IL-6, TNF-a, and IFN-g, as 
well as anti-inflammatory mediators IL-10 and TGF-b2. 
These mediators are important in preventing the pathogen 
from entering the bloodstream and spreading to organs. 
The higher IgA and IgM serum concentrations among the CF 
patients could be due to this adaptive immune response, 
which fails to adequately control lung infection and the 
progression of chronic lung disease. Furthermore, the exact 
risk factors for infection with nontuberculous mycobacteria 
remain largely unknown. The ability to control intracellular 
Mycobacterium infection relies on cellular immunity and 
generation of a strong T-cell helper 1 (TH1) response TNF-a 
or IL-1b.35 The lower TNF-a production from BCG-stimulated 
PBMC culture observed in the CF patients could be associated 
with higher risk for nontuberculous mycobacteria infection. 
Understanding these aspects will be essential for the 
development of improved therapies for CF.36 Further research 
is needed to elucidate the potential mechanisms involved in 
the inflammation in CF and its impact on clinical outcomes. 
Conclusion
Higher spontaneous production of TNF-a, IL-6, IL-10 and 
PHA-stimulated concentration of IL-6 were verified in PBMC 
cultures from CF patients, as well as higher TGF-b2, IgA, 
and IgM concentrations in their serum. Conversely, healthy 
subjects presented increased BCG-stimulated production 
of TNF-a. Therefore, it can be concluded that even in 
clinically stable CF patients a higher stimulation of the 
immune system (humoral and cellular immunity) occurs 
when compared to healthy subjects.
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